Long-term hazard of recurrence in HER2+breast cancer patients untreated with anti-HER2 therapy

Affiliation auteurs!!!! Error affiliation !!!!
TitreLong-term hazard of recurrence in HER2+breast cancer patients untreated with anti-HER2 therapy
Type de publicationJournal Article
Year of Publication2015
AuteursStrasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE
JournalBREAST CANCER RESEARCH
Volume17
Pagination56
Date PublishedAPR 16
Type of ArticleArticle
ISSN1465-5411
Résumé

{Introduction: Worldwide, many patients with HER2+ (human epidermal growth factor receptor 2-positive) early breast cancer (BC) do not receive adjuvant trastuzumab. Hazards of recurrence of these patients with respect to hormone receptor status of the primary tumor have not been described. Methods: Using data from 1,260 patients randomized to placebo in the adjuvant TEACH trial, we report 10-year annual hazards of recurrence in HER2+ patients not treated with anti-HER2 therapy. Results: Disease-free survival (DFS) was 75% after 5 and 61% after 10 years, respectively. Patients with HER2+ hormone receptor-positive (HR+ (hormone receptor-positive); ER+ (estrogen receptor-positive) or PR+ (progesterone receptor-positive)) disease had a significantly better DFS than patients with HER2+ HR-(ER-/PR-) disease (hazard ratio 0.72
DOI10.1186/s13058-015-0568-1